Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Enliven Therapeutics Q4 2024 GAAP EPS $(0.46) Beats $(0.52) Estimate

Author: Benzinga Newsdesk | March 13, 2025 03:22pm
Enliven Therapeutics (NASDAQ:ELVN) reported quarterly losses of $(0.46) per share which beat the analyst consensus estimate of $(0.52) by 11.54 percent. This is a 2.13 percent increase over losses of $(0.47) per share from the same period last year.

Posted In: ELVN


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist